Skip to main content
    • Aa
    • Aa

Targeting of the immune system in systemic lupus erythematosus

  • Meera Ramanujam (a1) and Anne Davidson (a1)

Systemic lupus erythematosus (SLE) is a complex immune disorder in which loss of tolerance to nucleic acid antigens and other crossreactive antigens is associated with the development of pathogenic autoantibodies that damage target organs, including the skin, joints, brain and kidney. New drugs based on modulation of the immune system are currently being developed for the treatment of SLE. Many of these new therapies do not globally suppress the immune system but target specific activation pathways relevant to SLE pathogenesis. Immune modulation in SLE is complicated by differences in the immune defects between patients and at different disease stages. Since both deficiency and hyperactivity of the immune system can give rise to SLE, the ultimate goal for SLE therapy is to restore homeostasis without affecting protective immune responses to pathogens. Here we review recent immunological advances that have enhanced our understanding of SLE pathogenesis and discuss how they may lead to the development of new treatment regimens.

Corresponding author
*Corresponding author: Anne Davidson, Feinstein Institute for Medical Research, NS-LIJHS, Autoimmune Laboratory, 350 Community Drive, Manhasset, NY 11030, USA. Tel: +1 516 562 3840; Fax: +1 516 562 2953; E-mail:
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

1H. Wardemann (2003) Predominant autoantibody production by early human B cell precursors. Science 301, 1374-1377

2M.R. Arbuckle (2003) Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349, 1526-1533

3A.M. Fairhurst , A.E. Wandstrat and E.K. Wakeland (2006) Systemic lupus erythematosus: multiple immunological phenotypes in a complex genetic disease. Adv Immunol 92, 1-69

4A.N. Theofilopoulos and D.H. Kono (1999) The genes of systemic autoimmunity. Proc Assoc Am Physicians 111, 228-240

5B.R. Lauwerys and E.K. Wakeland (2005) Genetics of lupus nephritis. Lupus 14, 2-12

6C.M. Grimaldi (2002) Estrogen alters thresholds for B cell apoptosis and activation. J Clin Invest 109, 1625-1633

8J.A. Mahoney and A. Rosen (2005) Apoptosis and autoimmunity. Curr Opin Immunol 17, 583-588

9J.S. Navratil , C.C. Liu and J.M. Ahearn (2006) Apoptosis and autoimmunity. Immunol Res 36, 3-12

11J.J. Manson , C. Mauri and M.R. Ehrenstein (2005) Natural serum IgM maintains immunological homeostasis and prevents autoimmunity. Springer Semin Immunopathol 26, 425-432

12A.P. Manderson , M. Botto and M.J. Walport (2004) The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol 22, 431-456

13M.A. Lee-Kirsch (2007) Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet 39, 1065-1067

14S.R. Christensen and M.J. Shlomchik (2007) Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptors. Semin Immunol 19, 11-23

15P.S. Lenert (2006) Targeting Toll-like receptor signaling in plasmacytoid dendritic cells and autoreactive B cells as a therapy for lupus. Arthritis Res Ther 8, 203

16H. Wagner and S. Bauer (2006) All is not Toll: new pathways in DNA recognition. J Exp Med 203, 265-268

17C.M. Lau (2005) RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med 202, 1171-1177

18H. Wagner (2006) Endogenous TLR ligands and autoimmunity. Adv Immunol 91, 159-173

19M. Rutz (2004) Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur J Immunol 34, 2541-2550

20S. Akira , S. Uematsu and O. Takeuchi (2006) Pathogen recognition and innate immunity. Cell 124, 783-801

21K. Honda , A. Takaoka and T. Taniguchi (2006) Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity 25, 349-360

22S. Pandey and D.K. Agrawal (2006) Immunobiology of Toll-like receptors: emerging trends. Immunol Cell Biol 84, 333-341

23S. Sigurdsson (2005) Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet 76, 528-537

24L. Ronnblom and G.V. Alm (2003) Systemic lupus erythematosus and the type I interferon system. Arthritis Res Ther 5, 68-75

25A. Mathian (2005) IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White) F1 but not in BALB/c mice. J Immunol 174, 2499-2506

26C. Pasare and R. Medzhitov (2003) Toll pathway-dependent blockade of CD4+ CD25+ T cell-mediated suppression by dendritic cells. Science 299, 1033-1036

27S.R. Krutzik (2005) TLR activation triggers the rapid differentiation of monocytes into macrophages and dendritic cells. Nat Med 11, 653-660

28E.C. Logue (2006) ICOS-induced B7 h shedding on B cells is inhibited by TLR7/8 and TLR9. J Immunol 177, 2356-2364

29M. Ehlers and J.V. Ravetch (2007) Opposing effects of Toll-like receptor stimulation induce autoimmunity or tolerance. Trends Immunol 28, 74-79

30J. Tian (2007) Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 8, 487-496

31S.R. Christensen (2006) Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25, 417-428

32M. Ehlers (2006) TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med 203, 553-561

33X. Wu and S.L. Peng (2006) Toll-like receptor 9 signaling protects against murine lupus. Arthritis Rheum 54, 336-342

34R. Berland (2006) Toll-like receptor 7-dependent loss of B cell tolerance in pathogenic autoantibody knockin mice. Immunity 25, 429-440

35P. Pisitkun (2006) Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 312, 1669-1672

36A. Akkerman (2004) CTLA4Ig prevents initiation but not evolution of anti-phospholipid syndrome in NZW/BXSB mice. Autoimmunity 37, 445-451

37H. Kanzler (2007) Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 13, 552-559

38L. Dong (2005) Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB x NZW mice. Arthritis Rheum 52, 651-658

39H.J. Anders and D. Schlondorff (2007) Toll-like receptors: emerging concepts in kidney disease. Curr Opin Nephrol Hypertens 16, 177-183

40F. Nimmerjahn and J.V. Ravetch (2006) Fcgamma receptors: old friends and new family members. Immunity 24, 19-28

41T.L. McGaha , B. Sorrentino and J.V. Ravetch (2005) Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science 307, 590-593

42M.R. Clatworthy (2007) Systemic lupus erythematosus-associated defects in the inhibitory receptor FcgammaRIIb reduce susceptibility to malaria. Proc Natl Acad Sci U S A 104, 7169-7174

43M. Mackay (2006) Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE. J Exp Med 203, 2157-2164

44K. Su (2007) Expression profile of FcgammaRIIb on leukocytes and its dysregulation in systemic lupus erythematosus. J Immunol 178, 3272-3280

45S. Bolland and J.V. Ravetch (2000) Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis. Immunity 13, 277-285

46H. Fukuyama , F. Nimmerjahn and J.V. Ravetch (2005) The inhibitory Fcgamma receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells. Nat Immunol 6, 99-106

47J.B. Harley , J.A. Kelly and K.M. Kaufman (2006) Unraveling the genetics of systemic lupus erythematosus. Springer Semin Immunopathol 28, 119-130

48F.B. Karassa , T.A. Trikalinos and J.P. Ioannidis (2004) The role of FcgammaRIIA and IIIA polymorphisms in autoimmune diseases. Biomed Pharmacother 58, 286-291

49F. Nimmerjahn and J.V. Ravetch (2007) The antiinflammatory activity of IgG: the intravenous IgG paradox. J Exp Med 204, 11-15

50B. Diamond (1992) The role of somatic mutation in the pathogenic anti-DNA response. Annu Rev Immunol 10, 731-757

51A.K. Abbas (2004) T cell tolerance and autoimmunity. Autoimmun Rev 3, 471-475

52M. Miyara and S. Sakaguchi (2007) Natural regulatory T cells: mechanisms of suppression. Trends Mol Med 13, 108-116

53A. Mondino and D.L. Mueller (2007) mTOR at the crossroads of T cell proliferation and tolerance. Semin Immunol 19, 162-172

54F. Vincenti and M. Luggen (2007) T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune diseases and transplantation. Annu Rev Med 58, 347-358

55J. Lohr (2003) The inhibitory function of B7 costimulators in T cell responses to foreign and self-antigens. Nat Immunol 4, 664-669

56A.L. Mellor (2003) Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol 171, 1652-1655

57A. Mellor (2005) Indoleamine 2,3 dioxygenase and regulation of T cell immunity. Biochem Biophys Res Commun 338, 20-24

58H. Ueda (2003) Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423, 506-511

60A. Davidson (2005) Block and tackle: CTLA4Ig takes on lupus. Lupus 14, 197-203

61L.W. Moreland (2002) Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 46, 1470-1479

62B.K. Finck , P.S. Linsley and D. Wofsy (1994) Treatment of murine lupus with CTLA4Ig. Science 265, 1225-1227

64X. Wang (2002) Mechanism of action of combined short-term CTLA4Ig and anti-CD40 ligand in murine systemic lupus erythematosus. J Immunol 168, 2046-2053

65L. Schiffer (2003) Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition. J Immunol 171, 489-497

66R.J. Greenwald , Y.E. Latchman and A.H. Sharpe (2002) Negative co-receptors on lymphocytes. Curr Opin Immunol 14, 391-396

68M. Lohning (2003) Expression of ICOS in vivo defines CD4+ effector T cells with high inflammatory potential and a strong bias for secretion of interleukin 10. J Exp Med 197, 181-193

69A.U. Rasheed (2006) Follicular B helper T cell activity is confined to CXCR5(hi)ICOS(hi) CD4 T cells and is independent of CD57 expression. Eur J Immunol 36, 1892-1903

70A.J. McAdam (2001) ICOS is critical for CD40-mediated antibody class switching. Nature 409, 102-105

71C. Dong (2001) ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature 409, 97-101

72R.A. Shilling , H.S. Bandukwala and A.I. Sperling (2006) Regulation of T:B cell interactions by the inducible costimulator molecule: does ICOS “induce” disease? Clin Immunol 121, 13-18

73A. Hutloff (2004) Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus. Arthritis Rheum 50, 3211-3220

74C.G. Vinuesa (2005) A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature 435, 452-458

75H. Iwai (2003) Involvement of inducible costimulator-B7 homologous protein costimulatory pathway in murine lupus nephritis. J Immunol 171, 2848-2854

76A.H. Sharpe (2007) The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 8, 239-245

77M.J. Ansari (2003) The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 198, 63-69

78B.T. Fife (2006) Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med 203, 2737-2747

79T. Okazaki , Y. Iwai and T. Honjo (2002) New regulatory co-receptors: inducible co-stimulator and PD-1. Curr Opin Immunol 14, 779-782

80L. Prokunina (2002) A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 32, 666-669

81N. Watanabe (2003) BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 4, 670-679

82J.R. Sedy (2005) B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat Immunol 6, 90-98

83R.J. Greenwald , G.J. Freeman and A.H. Sharpe (2005) The B7 family revisited. Annu Rev Immunol 23, 515-548

84J. Foell (2003) CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice. J Clin Invest 111, 1505-1518

85J. Kim (2005) Stimulation with 4-1BB (CD137) inhibits chronic graft-versus-host disease by inducing activation-induced cell death of donor CD4+ T cells. Blood 105, 2206-2213

86B.K. Choi (2004) 4-1BB-dependent inhibition of immunosuppression by activated CD4+ CD25+ T cells. J Leukoc Biol 75, 785-791

87Y. Sun (2002) Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat Med 8, 1405-1413

88B. Salomon and J.A. Bluestone (2001) Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 19, 225-252

89E. Castigli (1994) CD40-deficient mice generated by recombination-activating gene-2-deficient blastocyst complementation. Proc Natl Acad Sci U S A 91, 12135-12139

90I.S. Grewal and R.A. Flavell (1998) CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 16, 111-135

91L.A. Vogel and R.J. Noelle (1998) CD40 and its crucial role as a member of the TNFR family. Semin Immunol 10, 435-442

92X. Wang (2003) Effects of anti-CD154 treatment on B cells in murine systemic lupus erythematosus. Arthritis Rheum 48, 495-506

93P.I. Sidiropoulos and D.T. Boumpas (2004) Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 13, 391-397

94K.C. Kalunian (2002) Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46, 3251-3258

95D.T. Boumpas (2003) A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 48, 719-727

96W. Huang (2002) The effect of anti-CD40 ligand antibody on B cells in human SLE. Arthritis Rheum 46, 1554-1562

100A.P. Sutherland , F. Mackay and C.R. Mackay (2006) Targeting BAFF: immunomodulation for autoimmune diseases and lymphomas. Pharmacol Ther 112, 774-786

101M. Ramanujam and A. Davidson (2004) The current status of targeting BAFF/BLyS for autoimmune diseases. Arthritis Res Ther 6, 197-202

102F. Mackay (2003) BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 21, 231-264

103B.P. O'Connor (2004) BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 199, 91-98

104K. Ingold (2005) Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med 201, 1375-1383

105B. Schiemann (2001) An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 293, 2111-2114

106M. Ramanujam (2006) Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest 116, 724-734

107K.A. Vora (2003) Cutting edge: germinal centers formed in the absence of B cell-activating factor belonging to the TNF family exhibit impaired maturation and function. J Immunol 171, 547-551

108C.O. Jacob (2006) Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF. J Immunol 177, 2671-2680

109J.R. Groom (2007) BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med 204, 1959-1971

110R. Lesley (2004) Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 20, 441-453

111M. Thien (2004) Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20, 785-798

112F. Martin and A.C. Chan (2006) B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol 24, 467-496

113J. Zhang (2001) Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 166, 6-10

114G.S. Cheema (2001) Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 44, 1313-1319

115S.K. Chang (2006) A role for BLyS in the activation of innate immune cells. Blood 108, 2687-2694

116M. Ramanujam (2004) Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J Immunol 173, 3524-3534

120J. Uchida (2004) Mouse CD20 expression and function. Int Immunol 16, 119-129

122J. Uchida (2004) The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 199, 1659-1669

123Q. Gong (2005) Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 174, 817-826

124Y. Hamaguchi (2005) The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J Immunol 174, 4389-4399

125W.Y. Lin (2007) Anti-BR3 antibodies - a new class of B cell immunotherapy combining cellular depletion and survival blockade. Blood 110, 3959-3967

126P.P. Sfikakis , J.N. Boletis and G.C. Tsokos (2005) Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol 17, 550-557

127R.J. Looney (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50, 2580-2589

128M.J. Leandro (2002) An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 46, 2673-2677

129R.F. van Vollenhoven (2004) Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone. Scand J Rheumatol 33, 423-427

130J.H. Anolik (2003) The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 48, 455-459

131J.H. Anolik (2004) Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 50, 3580-3590

132M.J. Leandro (2006) Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 54, 613-620

133K.P. Ng (2007) B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis 66, 1259-1262

134T.F. Tedder (1997) CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu Rev Immunol 15, 481-504

135P.R. Crocker , J.C. Paulson and A. Varki (2007) Siglecs and their roles in the immune system. Nat Rev Immunol 7, 255-266

136K.L. Otipoby (1996) CD22 regulates thymus-independent responses and the lifespan of B cells. Nature 384, 634-637

137T.L. O'Keefe (1999) Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies. J Exp Med 189, 1307-1313

138J.P. Leonard (2004) Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin Cancer Res 10, 5327-5334

139T. Dorner (2006) Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 8, R74

140A.M. Jacobi (2007) Differential effects of epratuzumab on peripheral blood B cells of SLE patients versus normal controls. Ann Rheum Dis [doi:10.1136/ard.2007.075762]

141J. Carnahan (2007) Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol 44, 1331-1341

142D. Alarcon-Segovia (2003) LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 48, 442-454

143M. Wiesendanger (2006) Novel therapeutics for systemic lupus erythematosus. Curr Opin Rheumatol 18, 227-235

144C. Herrero (2003) Reprogramming of IL-10 activity and signaling by IFN-gamma. J Immunol 171, 5034-5041

145X. Hu (2007) Crosstalk among Jak-STAT, Toll-like receptor, and ITAM-dependent pathways in macrophage activation. J Leukoc Biol 82, 237-243

146B. Liang (2006) Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology 119, 296-305

147T. Kishimoto (2005) Interleukin-6: from basic science to medicine – 40 years in immunology. Annu Rev Immunol 23, 1-21

148M. Mihara , N. Nishimoto and Y. Ohsugi (2005) The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody. Expert Opin Biol Ther 5, 683-690

150E. Tackey , P.E. Lipsky and G.G. Illei (2004) Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 13, 339-343

151M. Mihara (1998) IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice. Clin Exp Immunol 112, 397-402

152B.K. Finck , B. Chan and D. Wofsy (1994) Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J Clin Invest 94, 585-591

154C.M. Hill and J. Lunec (1996) The TNF-ligand and receptor superfamilies: controllers of immunity and the Trojan horses of autoimmune disease? Mol Aspects Med. 17, 455-509

155C.O. Jacob and H.O. McDevitt (1988) Tumour necrosis factor-alpha in murine autoimmune ‘lupus’ nephritis. Nature 331, 356-358

156D. Kontoyiannis and G. Kollias (2000) Accelerated autoimmunity and lupus nephritis in NZB mice with an engineered heterozygous deficiency in tumor necrosis factor. Eur J Immunol 30, 2038-2047

157J.D. Mountz (2001) Re: collagen-induced arthritis in TNF receptor-1-deficient mice: TNF receptor-2 can modulate arthritis in the absence of TNF receptor 1. Clin Immunol 99, 305-307

158E. Romas , M.T. Gillespie and T.J. Martin (2002) Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone 30, 340-346

159M. Feldmann and R.N. Maini (2001) Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 19, 163-196

160W.J. Sandborn and S.B. Hanauer (1999) Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 5, 119-133

161M. Feldmann and R.N. Maini (2003) Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 9, 1245-1250

162A.M. Tobin and B. Kirby (2005) TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. BioDrugs 19, 47-57

163G. Kollias (2005) TNF pathophysiology in murine models of chronic inflammation and autoimmunity. Semin Arthritis Rheum 34, 3-6

164V.J. Swale (2003) Etanercept-induced systemic lupus erythematosus. Clin Exp Dermatol 28, 604-607

165P.G. Tipping and S.R. Holdsworth (2007) Cytokines in glomerulonephritis. Semin Nephrol 27, 275-285

166M. Aringer (2004) Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 50, 3161-3169

167M. Aringer (2007) Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis Rheum 56, 274-279

168X. Valencia (2007) Deficient CD4+ CD25 high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 178, 2579-2588

169F.K. Chan and M.J. Lenardo (2002) Tumor Necrosis Factor Family Ligands and Receptors in the Immune System: Targets for Future Pharmaceuticals. Drug News Perspect 15, 483-490

170R.M. Locksley , N. Killeen and M.J. Lenardo (2001) The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104, 487-501

171Y.X. Fu and D.D. Chaplin (1999) Development and maturation of secondary lymphoid tissues. Annu Rev Immunol 17, 399-433

172G. Kassiotis and G. Kollias (2001) Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J Exp Med 193, 427-434

173V. Pascual , L. Farkas and J. Banchereau (2006) Systemic lupus erythematosus: all roads lead to type I interferons. Curr Opin Immunol 18, 676-682

174L. Ronnblom and G.V. Alm (2002) The natural interferon-alpha producing cells in systemic lupus erythematosus. Hum Immunol 63, 1181-1193

175L. Bennett (2003) Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 197, 711-723

176E.C. Baechler (2003) Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 100, 2610-2615

177S. Koutouzov , A. Mathian and A. Dalloul (2006) Type-I interferons and systemic lupus erythematosus. Autoimmun Rev 5, 554-562

178J.A. Meyers (2006) Blockade of TLR9 agonist-induced type I interferons promotes inflammatory cytokine IFN-gamma and IL-17 secretion by activated human PBMC. Cytokine 35, 235-246

179T. Nagai (2003) Timing of IFN-beta exposure during human dendritic cell maturation and naive Th cell stimulation has contrasting effects on Th1 subset generation: a role for IFN-beta-mediated regulation of IL-12 family cytokines and IL-18 in naive Th cell differentiation. J Immunol 171, 5233-5243

180K.M. Dhodapkar (2007) Selective blockade of the inhibitory Fc gamma receptor (Fc gamma RIIB) in human dendritic cells and monocytes induces a type I interferon response program. J Exp Med 204, 1359-1369

182E. Hagiwara (1996) Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10: interferon-gamma-secreting cells in the peripheral blood. Arthritis Rheum 39, 379-385

183J.D. Ji (2003) Inhibition of interleukin 10 signaling after Fc receptor ligation and during rheumatoid arthritis. J Exp Med 197, 1573-1583

184H. Ishida (1994) Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 179, 305-310

186Z. Yin (2002) IL-10 regulates murine lupus. J Immunol 169, 2148-2155

187L. Llorente (2000) Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 43, 1790-1800

188C.O. Jacob , P.H. van der Meide and H.O. McDevitt (1987) In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon. J Exp Med 166, 798-803

189L. Ozmen (1995) Experimental therapy of systemic lupus erythematosus: the treatment of NZB/W mice with mouse soluble interferon-gamma receptor inhibits the onset of glomerulonephritis. Eur J Immunol 25, 6-12

190D. Balomenos , R. Rumold and A.N. Theofilopoulos (1998) Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J Clin Invest 101, 364-371

191R.R. Singh (2003) Differential contribution of IL-4 and STAT6 vs STAT4 to the development of lupus nephritis. J Immunol 170, 4818-4825

192C.T. Weaver (2007) IL-17 Family Cytokines and the Expanding Diversity of Effector T Cell Lineages. Annu Rev Immunol 25, 821-852

193R. Clynes , C. Dumitru and J.V. Ravetch (1998) Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 279, 1052-1054

194A. Bergtold (2006) FcR-bearing myeloid cells are responsible for triggering murine lupus nephritis. J Immunol 177, 7287-7295

195O.T. Chan (1999) A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 189, 1639-1648

196K. Matsumoto (2003) Fc receptor-independent development of autoimmune glomerulonephritis in lupus-prone MRL/lpr mice. Arthritis Rheum 48, 486-494

197K.S. Peterson (2004) Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. J Clin Invest 113, 1722-1733

198H.J. Anders (2004) Late onset of treatment with a chemokine receptor CCR1 antagonist prevents progression of lupus nephritis in MRL-Fas(lpr) mice. J Am Soc Nephrol 15, 1504-1513

199H.J. Anders , V. Ninichuk and D. Schlondorff (2006) Progression of kidney disease: blocking leukocyte recruitment with chemokine receptor CCR1 antagonists. Kidney Int 69, 29-32

202A.N. Theofilopoulos and F.J. Dixon (1985) Murine models of systemic lupus erythematosus. Adv Immunol 37, 269-390

203R. Furie (2006) Abetimus sodium (riquent) for the prevention of nephritic flares in patients with systemic lupus erythematosus. Rheum Dis Clin North Am 32, 149-156

204J.C. Davis Jr. (1999) Recombinant human DNase I (rhDNase) in patients with lupus nephritis. Lupus 8, 68-76

205I. Gunnarsson (2007) Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 56, 1263-1272

206R. Eisenberg (2006) Targeting B cells in SLE: the experience with rituximab treatment (anti-CD20). Endocr Metab Immune Disord Drug Targets 6, 345-350

208M. Kilmon (2005) Low-affinity, Smith antigen-specific B cells are tolerized by dendritic cells and macrophages. J Immunol 175, 37-41

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *